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 The promise of biomarkers for 
personalized renal cancer care 
 Prasad  Devarajan 1 
 Biomarkers hold promise for personalizing renal cancer care by 
potentially identifying patients most likely to benefit from novel 
therapies. Porta and colleagues report that among subjects with 
advanced renal-cell carcinoma receiving sunitinib treatment, those with 
above-normal levels of the circulating biomarkers vascular endothelial 
growth factor and neutrophil gelatinase-associated lipocalin displayed 
significantly lower progression-free survival times. This Commentary 
reviews the current status of these biomarkers with respect to 
methodological issues, specificity, and biological plausibility. 
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 The era of personalized medicine is well 
upon us. Ushered in by the remarkable 
genomic and proteomic advances in our 
understanding of health and disease, 
personalized medicine promises a more 
precise determination of disease predis-
position, diagnosis, and prognosis, 
earlier preventive and therapeutic inter-
ventions, a more effi  cient drug develop-
ment process, and a safer and more 
fi scally responsive approach to medicine. 
Biomarkers are the essential tools for the 
implementation of personalized medi-
cine. Broadly defi ned as characteristics 
that are objectively evaluated as indica-
tors of normal biological processes, path-
ogenic processes, or pharmacologic 
responses, biomarkers have already revo-
lutionized several facets of medicine. 
Particularly in the fi eld of oncology, spe-
cifi c biomarkers such as HER2 (erbB2) 
and EGFR now allow us to individualize 
therapies for patients with breast and 
colorectal cancers. However, we have 
only begun to scratch the tip of the 
 proverbial iceberg — as medical break-
throughs continue to identify novel 
agents for malignancies that are poten-
tially eff ective but also inevitably toxic 
and expensive, biomarkers will be 
indispensible for patient selection, risk 
stratifi cation, and prognostication. 
 Consider the case in hand: renal-cell car-
cinoma (RCC), the most common kidney 
cancer in adults and clearly the most lethal 
of all advanced genitourinary tumors. For-
tunately, an improved understanding of the 
underlying molecular bio logy has begun to 
identify novel targeted therapies. In kidney 
tubule cells, the pro duct of the  VHL tumor 
suppressor gene normally inhibits the pro-
duction of hypoxia-inducible factors such 
as vascular endothelial growth factor 
(VEGF) and platelet-derived growth factor 
(PDGF). Inactivation of the  VHL gene, as 
occurs in the majority of clear-cell carcino-
mas (the predominant type of renal-cell 
carcinoma), results in overexpression of 
these factors, and stimulation of the cog-
nate VEGF and PDGF receptors, respec-
tively. Persistent activation of the receptors ’ 
intrinsic tyrosine kinase results in signaling 
through cellular pathways that stimulate 
growth, proliferation, and angiogenesis and 
inhibit apoptosis, thereby resulting in met-
astatic RCC. 1 Sunitinib, an orally active 
agent that inhibits the receptor tyrosine 
kinases VEGFR types 1 and 2 and PDGFR-
  and PDGFR-  , has shown promise in 
prolonging progression-free survival in 
some patients with advanced RCC. 2 How-
ever, individual responses have varied 
unpredictably, side eff ects are myriad, and 
overall mortality has remained largely una-
bated. Herein lies the dilemma — how do 
we personalize this novel therapy to best 
identify the subset of patients who are most 
likely to benefi t from it? 
 Porta and colleagues 3 (this issue) have 
appropriately called on biomarkers to 
tackle this question. In 85 subjects with 
advanced RCC who were treated with 
sunitinib, the authors have compared the 
ability of an existing clinicopathologic 
scoring system (Motzer criteria) versus 
serum biomarkers at enrollment as pre-
dictors of progression-free survival. In 
their cohort, the baseline concentrations 
of both chosen biomarkers, VEGF and 
neutrophil gelatinase-associated lipoca-
lin (NGAL), were found to correlate with 
progression-free survival, whereas the 
Motzer score did not. When subjects 
were dichotomized to normal versus 
high circulating biomarker levels, those 
with values above a threshold (determined 
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by normal ranges according to the 
manufacturers of the research-based 
ELISAs used) were found to have sig-
nificantly diminished progression-free 
survival rates. 
 Like all good pilot studies, the report of 
Porta  et al. 3 raises several questions that will 
need to be answered in future studies. First, 
an ideal biomarker should be easily meas-
ured, preferably with the use of standard-
ized clinical platforms. Such a platform is 
now available for plasma NGAL, 4 but VEGF 
measurements continue to rely on research-
based assays, which have been fraught with 
inconsistencies depending on the method 
of sample collection, processing, and inter-
pretation. 5 Th e authors ’ choice to measure 
VEGF in the serum instead of the plasma 
may be particularly problematic. VEGF is 
normally stored in circulating platelets, and 
released during the clotting process. Th ere-
fore, serum VEGF concentrations may 
refl ect blood platelet degranulation  in vitro 
rather than VEGF synthesis by peripheral 
tissues. Second, the diagnostic accuracy of 
a biomarker is best assessed by the con-
struction of receiver operating characteris-
tic curves and determination of the area 
under the curve. 6 Such analysis can also 
provide biomarker concentration cutoff s 
that maximize the sensitivity and specifi city 
to predict an outcome. Th ird, serial meas-
urements of the biomarkers during the 
course of therapy may provide additional 
predictive information in comparison with 
a single baseline biomarker measurement. 
 Fourth, and perhaps most importantly, 
an ideal biomarker should be specifi c and 
attributable to a known mechanism. In 
RCC, the choice of VEGF is biologically 
plausible, based on the well-documented 
overproduction of this cytokine by clear-
cell carcinoma cells with  VHL mutations. 
However, there exist issues of biomarker 
specifi city — increases in circulating VEGF 
levels accompany any angiogenic process, 
including diverse tumors, hypoxic states, 
anemia, diabetes, wound healing, and pul-
monary hypertension, to name a few. Th e 
fact that sunitinib itself increases plasma 
VEGF levels further complicates the use of 
this biomarker once pharmacotherapy for 
RCC has begun. 
 What about the specifi city of NGAL as a 
potential circulating biomarker in RCC? In 
the past few years, NGAL has advanced to 
center stage as an early predictive biomar-
ker of acute kidney injury 7 as well as 
chronic kidney disease. 8 However, the pre-
cise sources of plasma NGAL in these con-
ditions have remained controversial. 
Human NGAL was originally identifi ed as 
a 25-kDa protein covalently bound to 
matrix metalloproteinase-9 (MMP-9) from 
neutrophils. NGAL is expressed at low lev-
els in several human tissues but is markedly 
induced in injured epithelia, including the 
kidney, colon, liver, and lung. Th e overex-
pressed NGAL protein released into the 
circulation may contribute to the systemic 
pool. In addition, NGAL is an acute-phase 
reactant that may be released into the 
plasma from activated neutrophils, macro-
phages, other immune cells, and even 
atherosclerotic plaques. Also, both anemia 
and hypoxia can upregulate hepatic NGAL 
synthesis with resultant increases in plasma 
NGAL levels. Furthermore, any decrease 
in glomerular fi ltration rate resulting from 
acute or chronic kidney disease (or 
nephrectomies in the case of RCC) would 
be expected to decrease the renal clearance 
of NGAL, with subsequent accumulation 
in the systemic circulation. All these poten-
tial vari ables may diminish the specifi city 
of NGAL as a biomarker in advanced RCC 
( Figure 1 ). 
 With respect to biomarker plausibility, it 
is instructive to ponder the potential roles 
that NGAL could play ( Figure 1 ). Teleolog-
ically, NGAL constitutes a critical compo-
nent of innate immunity to exogenous 
bacterial infections. Siderophores are prom-
inent ligands for NGAL, and bacteria pro-
duce siderophores to shuttle iron from the 
extracellular space. Th e siderophore-chelat-
ing property of NGAL therefore renders it 
a bacteriostatic agent. 9 However, in the con-
text of an injured organ such as the kidney, 
the biological role of NGAL induction is 
one of marked preservation of function, 
attenuation of apoptosis, and an enhanced 
proliferative response. 10 This protective 
eff ect is dependent on the chelation of toxic 
iron from extracellular environments, and 
the regulated delivery of siderophore and 
iron to intracellular sites. And fi nally, NGAL 
is markedly induced in a number of human 
cancers, where it oft en represents a predic-
tor of poor prognosis. 9 Th e  NGAL gene 
(also known as  LCN2 , for lipocalin 2) is 
known to be induced by a number of 
tumor-promoting agents, including SV40 
and polyoma virus, phorbol esters, the 
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 Figure 1  |  Multiple factors may determine plasma NGAL concentrations. The cellular role 
of neutrophil gelatinase-associated lipocalin (NGAL) may be largely dependent on the type of 
molecule it is complexed with.  ‘ Apo-NGAL ’ denotes NGAL that is devoid of siderophore or iron. ECM, 
extracellular matrix; MMP-9, matrix metalloproteinase-9; VEGF, vascular endothelial growth factor. 
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transforming factor  neu , hepatocyte growth 
factor, retinoic acid, glucocorticoids, and 
nuclear factor-  B. The overexpressed 
NGAL protein binds to MMP-9, thereby 
preventing MMP-9 degradation and 
increasing MMP-9 enzyme activity. In turn, 
MMP-9 activity promotes cancer progres-
sion by degrading the basement mem-
branes and extracellular matrix, liberating 
VEGF, and thus enabling angiogenesis, 
invasion, and metastasis. Paradoxically, 
recent studies in several tumor cell lines 
have shown that NGAL enhanced the epi-
thelial phenotype, reduced tumor growth, 
and suppressed metastasis; this prosurvival 
activity of NGAL is mediated by its ability 
to bind and transport iron inside the cells. 9 
Especially pertinent to the study by Porta 
 et al. 3 are recent fi ndings that (1) NGAL is 
induced by hypoxia and may indeed be 
driven by the pro-neoplastic hypoxia-
inducible factor-1  (HIF-1  ), which in 
turn is regulated by  VHL ; (2) NGAL can 
inhibit HIF-1  ; and (3) NGAL can inhibit 
VEGF synthesis. 
 How does one reconcile the seemingly 
contradictory roles of NGAL in human 
biology? A potentially unifying hypoth-
esis is off ered in  Figure 1 . Effi  cient mech-
anisms have evolved for the intracellular 
uptake of NGAL via receptors such as 
megalin, and for intracellular traffi  cking 
via endosomes. Th e subsequent molecu-
lar path taken by NGAL may be largely 
dependent on the type of molecule it is 
complexed with. NGAL that is devoid of 
siderophore and iron (holo-NGAL) rap-
idly scavenges intracellular iron. The 
resultant intracellular iron depletion 
results in a decrease in the mammalian 
cell ’ s proliferative ability and in induc-
tion of apoptosis. On the other hand, 
when NGAL is bound to siderophore 
and iron, there is a rapid release of iron 
with regulation of iron-dependent 
molecular pathways and downstream 
induction of proliferation and epithelial 
transformation. Finally, when NGAL is 
complexed with MMP-9 instead, there is 
enhancement of the active MMP-9 pool 
with resultant upregulation of MMP-9 ’ s 
well-known proangiogenic and proinva-
sive properties. Future studies aimed at 
further testing these hypotheses hold 
promise for advancing our understand-
ing of tumor biology, and for potentially 
validating NGAL as a biomarker for per-
sonalizing renal cancer care. 
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 LECT2 amyloidosis 
 Merrill D.  Benson 1 
 LECT2 amyloidosis is the latest systemic type of amyloidosis to be 
described. It was discovered in patients with nephrotic syndrome and 
renal failure and is characterized by amyloid deposition in glomeruli, 
renal vessels, and interstitium. Clinical and pathological features of 
earlier phases of this type of amyloidosis have yet to be determined. 
 Kidney International (2010)  77, 757 – 759.  doi: 10.1038/ki.2010.18 
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 In 1971 Glenner  et al. reported the amino 
acid structure of monoclonal immuno-
globulin light chain (AL) protein isolated 
from tissues of a patient with primary 
amyloidosis. 1 Th is was the fi rst human 
amyloid protein to be chemically charac-
terized. Structural characterization of 
human secondary amyloid protein (serum 
amyloid A (SAA)) was soon to follow in 
1972, 2 and since then, eight additional 
proteins associated with human systemic 
amyloidosis have been identified, for a 
total of ten ( Table 1 ). Th e latest of these 
amyloid proteins is leukocyte chemotactic 
factor 2 (LECT2), which, so far, appears 
mainly to cause renal amyloidosis. 3 
 LECT2 amyloid was originally discov-
ered in a patient who had nephrotic syn-
drome and slowly progressive renal failure 
over a number of years ( Figure 1 ). Clinical 
evaluation and renal biopsy studies failed 
to determine the type of amyloidosis, and 
only when the patient developed renal-cell 
carcinoma, which necessitated nephrec-
tomy, did amyloid-laden tissue become 
available for biochemical analysis. With-
out this chain of events and the inquisitive 
mind of the renal pathologist, it is unlikely 
that the correct diagnosis for this patient 
would have been made, and LECT2 
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